KALA BIO Settles Approximately $10.6 million of Debt
Rhea-AI Summary
KALA BIO (NASDAQ:KALA) announced it has completed a loan settlement with Oxford Finance, resolving approximately $10.6 million of debt as of December 26, 2025. The company made a $2.0 million payment required under a November 25, 2025 Loan Settlement Agreement, which fully satisfied obligations under the Settlement Agreement and the underlying May 4, 2021 Loan Agreement.
Management said the settlement removes a material overhang and increases strategic flexibility. Separately, on December 30, 2025, the board approved inducement grants totaling 400,000 common shares to four new employees.
AI-generated analysis. Not financial advice.
Positive
- Settled approximately $10.6 million of debt as of December 26, 2025
- Completed required $2.0 million payment to Oxford Finance, discharging loan obligations
Negative
- Granted 400,000 common shares as inducements on December 30, 2025, which may dilute existing shareholders
News Market Reaction – KALA
On the day this news was published, KALA gained 6.90%, reflecting a notable positive market reaction. Argus tracked a peak move of +48.8% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $988K to the company's valuation, bringing the market cap to $15.31M at that time. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KALA gained 11.73% while peers were mixed: BMEA up 6.35%, CRBP down 4.02%, EQ down 2.55%, IKT down 5.8%, TARA roughly flat. This points to a company-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Equity offering | Negative | -14.3% | Registered direct equity financing to raise $10M mainly for debt repayment. |
| Dec 04 | Equity offering | Negative | +13.5% | Announcement of at-the-market $10M registered direct equity deal. |
| Dec 01 | Financing/leadership | Positive | +37.7% | $6M securities purchase agreement and appointment of David Lazar as CEO. |
| Sep 29 | Clinical failure | Negative | -89.3% | CHASE Phase 2b trial for KPI-012 failed endpoints; program and platform discontinued. |
| Sep 03 | Conference participation | Positive | +23.1% | Presentation at H.C. Wainwright conference with investor meetings scheduled. |
KALA has sold off sharply on negative clinical outcomes and debt stress, while financing and strategic updates have produced volatile but often positive reactions. Offerings tied to debt repayment drew mixed responses.
Over the last six months, KALA moved from a failed CHASE Phase 2b trial and cessation of KPI-012/MSC-S development on Sep 29, 2025 to aggressive restructuring. The company executed workforce reductions and faced an Oxford default and cash sweep, with substantial doubt about going concern in Q3 2025. Subsequent financings, including a $6.0 million securities purchase agreement and a $10 million registered direct offering in early December, were aimed at repaying indebtedness. Today’s settlement of approximately $10.6 million of Oxford debt continues that balance sheet repair trajectory.
Market Pulse Summary
The stock moved +6.9% in the session following this news. A strong positive reaction aligns with KALA’s pattern of sharp moves around balance sheet and strategic updates. The settlement of approximately $10.6 million of Oxford debt after a $2 million payment removes a key liability from prior default events. However, past financings and offerings, including the recent $10 million raise, show that equity dilution and legacy operational risks have been significant, which could still influence how durable any rally becomes.
Key Terms
loan settlement agreement financial
events of default financial
loan and security agreement financial
common stock awards financial
AI-generated analysis. Not financial advice.
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations.
As previously disclosed in the Company’s Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford
Recently, KALA completed its
“The successful completion of the Oxford settlement represents a watershed moment for KALA BIO,” said David E. Lazar, Chief Executive Officer and Chairman of the Board. “By settling the Company’s debt obligations and increasing stockholders’ equity, we have removed a substantial overhang that was constraining the Company’s strategic flexibility. We are confident in our path forward.”
Also, as of December 30, 2025, the Company, with the Compensation Committee of KALA’s Board of Directors’ approval, granted common stock awards as a material inducement to employment to four individuals hired by KALA, which common stock awards relate to, in the aggregate, 400,000 shares of common stock.
KALA Contact
David Lazar
Chief Executive Officer and Chairman of the Board
david@activistinvestingllc.com
